Elevated factor VII as a risk factor for recurrent fetal loss

Summary

Haemostatic abnormalities can be detected in a portion of the women who have recurrent fetal loss. We measured factor VII coagulant activity (FVII:C) in 65 women with 3 or more fetal losses (recurrent cases), 31 women with one 2nd or 3rd trimester loss (late loss cases), and 81 women with only live births (controls). FVII:C was greater than 2 standard deviations above the mean for controls in 9 recurrent cases (13.8%) and 2 controls (2.5%) for an odds ratio of 6.35 (95% CI 1.32–30.52, p=0.012). In recurrent cases, mean levels were significantly higher than controls for FVII:C (p=0.003), FVII antigen (p=0.024), and FVIIa (p=0.001). Late loss cases had an odds ratio of 4.23 (95% CI 0.67–26.67, p=0.098) with FVII:C, FVII antigen, and FVIIa not significantly different from the controls. DNA was examined for the presence of mutations or polymorphisms in the promoter region of the FVII gene, using denaturing HPLC. Abnormal patterns were confirmed with direct sequencing. A previously reported polymorphism,–402 G>A, was found to be present in 11/14 subjects with elevated FVII:C (79%) and 43% of those with normal levels (p=0.029). FVII:C, FVII antigen and FVIIa varied significantly with genotype; however, genotype frequencies did not differ between controls and either case group. No other promoter polymorphisms were identified. This is the first report of a significant elevation of FVII in a population with recurrent fetal loss. These data suggest the need for further investigation of this potential risk factor.

Keywords

Factor VII - factor VII polymorphisms - fetal loss - recurrent fetal loss

^* Current address: Worldwide Epidemiology, Glaxo Smith Kline Research & Development.

• References

• 1 Brenner B. Inherited thrombophilia and pregnancy loss. Baillieres Best Pract Res Clin Haematol 2003; 16: 311-20.
• 2 Rey E, Kahn SR, David M. et al. Thrombophilic disorders and fetal loss: a meta-analysis. Lancet 2003; 361: 901-8.
• 3 Preston FE, Rosendaal FR, Walker ID. et al. Increased fetal loss in women with heritable thrombophilia. Lancet 1996; 348: 913-6.
• 4 Lanir N, Aharon A, Brenner B. Haemostatic mechanisms in human placenta. Baillieres Best Pract Res Clin Haematol 2003; 16: 183-95.
• 5 Rao LV, Rapaport I S. Activation of factor VII bound to tissue factor: a key early step in the tissue factor pathway of blood coagulation. Proc Natl Acad Sci U S A 1988; 85: 6687-91.
• 6 Rapaport I S, Rao LV. Initiation and regulation of tissue factor-dependent blood coagulation. Arterioscler Thromb 1992; 12: 1111-21.
• 7 Meade TW, Mellows S, Brozovic M. et al. Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet 1986; 2: 533-7.
• 8 Junker R, Heinrich J, Schulte H. et al. Coagulation factor VII and the risk of coronary heart disease in healthy men. Arterioscler Thromb 1997; 17: 1539-44.
• 9 Redondo M, Watzke HH, Stucki B. et al. Coagulation factors II, V, VII, and X, prothrombin gene 20210G>A transition, and factor V Leiden in coronary artery disease: high factor V clotting activity is an independent risk factor for myocardial infarction. Arterioscler Thromb Vasc Biol 1999; 19: 1020-5.
• 10 Folsom AR, Wu KK, Rosamond WD. et al. Prospective study of hemostatic factors and incidence of coronary heart disease: the Arthritis Risk in Communities (ARIC) Study. Circulation 1997; 96: 1102-8.
• 11 Smith FB, Lee AJ, Fowkes FGR. et al. Hemostatic factors as predictors of ischemic heart disease and stroke in the Edinburgh Artery Study. Arterioscler Thromb Vasc Biol 1997; 17: 3321-5.
• 12 Green F, Kelleher C, Wilkes H. et al. A common genetic polymorphism associated with lower factor VII levels in healthy individuals. Arterioscler Thromb 1991; 11: 540-6.
• 13 Marchetti G, Patracchini P, Papaschini M. et al. A polymorphism in the 5’region of coagulation factor VII gene (F7) caused by an inserted decanucleotide. Hum Genet 1993; 90: 575-6.
• 14 Van’t Hooft FM, Silveira A, Tornvall P. et al. Two common functional polymorphisms in the promoter region of the coagulation factor VII gene determining plasma factor VII activity and mass concentration. Blood 1999; 93: 3432-41.
• 15 Peyvandi F, Mannucci PM, Bucciarelli P. et al. A novel polymorphism in intron 1a of the human factor VII gene (G73A): a study of a healthy Italian population and of 190 young survivors of myocardial infarction. Br J Haematol 2000; 108: 247-53.
• 16 Pinotti M, Tosco R, Girelli D. et al. Modulation of factor VII levels by intron 7 polymorphisms: population and in vitro studies. Blood 2000; 95: 3423-8.
• 17 Lane A, Green F, Scarabin PY. et al. Factor VII Arg/ Gln polymorphism determines factor VII coagulant activity in patients with myocardial infarction (MI) and control subjects in Belfast and in France but is not a strong indicator of MI risk in the ECTIM study. Atherosclerosis 1996; 119: 119-27.
• 18 Wang XL, Wang J, McCredie RM. et al. Polymorphisms of factor V, factor VII, and fibrinogen genes: relevance to severity of coronary artery disease. Arterioscler Thromb Biol 1997; 17: 246-51.
• 19 Feng DL, Tofler GH, Larson MG. et al. Factor VII gene polymorphism, factor VII levels, and prevalent cardiovascular disease: the Framingham Heart Study. Arterioscler Thromb Vasc Biol 2000; 20: 593-600.
• 20 Carew JA, Basso F, Miller GJ. et al. A functional haplotype in the 5’ flanking region of the factor VII gene is associated with an increased risk of coronary heart disease. J Thromb Haemost 2003; 1: 2179-85.
• 21 Koster T, Rosendaal FR, Reitsma PH. et al. Factor VII and fibrinogen levels as risk factors for venous thrombosis – A case-control study of plasma levels and DNA polymorphisms – The Leiden Thrombophilia Study (LETS). Thromb Haemst 1994; 71: 719-22.
• 22 Austin H, Hooper WC, Lally C. et al. Venous thrombosis in relation to fibrinogen and factor VII genes among African-Americans. J Clin Epidemiol 2000; 53: 997-1001.
• 23 Dalaker K. Clotting factor VII during pregnancy, delivery and puerperium. Brit J Obstet Gynaecol 1986; 93: 17-21.
• 24 De Moerloose P, Amiral J, Vissac AM. et al. Longitudinal study on activated factors XII and VII levels during normal pregnancy. Br J Haematol 1998; 100: 40-4.
• 25 Wright D, Poller L, Thomson JM. et al. A longitudinal study of the factor VII rise during pregnancy. Thromb Haemost 1998; 79: 328-30.
• 26 Scarabin PY, Bonithon-Kopp C, Bara L. et al. Is factor VII activation in pregnant women relevant to foetal growth retardation?. Thromb Res 1987; 45: 845-50.
• 27 Dilley A, Benito C, Hooper WC. et al. Mutations in the factor V, prothrombin and MTHFR genes are not risk factors for recurrent fetal loss. J Matern Fet Neonat Med 2002; 11: 176-82.
• 28 O’Hara PJ, Grant FJ, Haldeman BA. et al. Nucleotide sequence of the gene coding for human factor VII, a vitamin K-dependent protein participating in blood coagulation. Proc Natl Acad Sci USA 1987; 84: 5158-62.
• 29 Erdmann D, Heim J. Orphan nuclear receptor HNF-4 binds to the human coagulation factor VII promoter. J Biol Chem 1995; 270: 22988-96.
• 30 Rothman KJ, Greenland S. Modern Epidemiology. 1998. Philadelphia: Lippincott-Raven Publishers;
• 31 Scarabin PY, Vissac AM, Kirzin JM. et al. Population correlates of coagulation factor VII: importance of age, sex, and menopausal status as determinants of activated factor VII. Arterioscler Thromb Vasc Biol 1996; 16: 1170-6.
• 32 Bloemenkamp KWM, de Maat MPM, Dersjant-Roorda MC. et al. Genetic polymorphisms modify the response of factor VII to oral contraceptive use: an example of gene-environment interaction. Vasc Pharmacol 2002; 39: 121-6.
• 33 Middeldorp S, Meijers CJM, van den Ende AE et al. Effects on coagulation of levonorgestrel- and desogestrel- containing low dose oral contraceptives: a crossover study. Thromb Haemost 2000; 84: 4-8.
• 34 Hunault M, Arbini AA, Lopaciuk S. et al. The Arg353Gln polymorphism reduces the level of coagulation factor VII: in vivo and in vitro studies. Arterioscler Thromb Vasc Biol 1997; 17: 2825-9.
• 35 Mann KG. Factor VII assays, plasma triglyceride levels, and cardiovascular disease risk. Arteriosclerosis 1989; 9: 783
• 36 Miller GJ, Stirling Y, Esnouf MP. et al. Factor VIIdeficiency substrate plasma depleted of protein C raise the sensitivity of the factor VII bio-assay to activated factor VII: an international study. Thromb Haemost 1994; 71: 38-48.
• 37 Morrissey JH, Macik BG, Neuenschwander PF. et al. Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation. Blood 1993; 81: 734-44.
• 38 Torry DS, Labarrere CA, McIntyre JA. Uteroplacental vascular involvement in recurrent spontaneous abortion. Curr Opinion Obstet Gynecol 1998; 10: 379-82.
• 39 Salafia CM. Placental pathology of fetal growth restriction. Clin Obstet Gynecol 1997; 40: 740-9.